To review research on screening for gestational diabetes mellitus (GDM). The review focused on the diagnostic performance and costs of various screening methods. The authors also assessed GDM screening against the criteria of the UK National Screening Committee.
Two reviewers extracted the data. The reviewers extracted the sensitivity, specificity and PPV of the screening tests used and, if sufficient data were provided in the primary studies, these calculations were checked. Other data extracted included thresholds for determining GDM, incidence of GDM in the study population, length of gestation, time since eating, and other outcomes as reported in the primary studies. In the summary of results, glucose levels were presented in mmol/L, using a conversion factor if necessary (1mg/dL = 0.0555mmol/L). In addition, equivalent plasma values were given for studies that presented results as whole blood glucose (plasma glucose equals whole blood glucose multiplied by 1.14).
Methods of synthesis
How were the studies combined? The studies were combined in a narrative summary. In addition, details of each study were tabulated. An assessment of screening for GDM, against the National Screening Committee criteria, was also provided. This was based partially upon the findings of the review.
How were differences between studies investigated? Within the summary, the studies were grouped according to the screening test under evaluation. Comparisons of screening tests were discussed separately. The authors provided a qualitative discussion of differences between the studies, commenting on factors such as the prevalence of GDM in the population used for a particular study, and thresholds used in the screening tests.
Results of the review
The review included 135 studies (>290,000 patients); not all reported data on diagnostic performance.Most of the studies were case series; some were observational studies, or controlled trials of varying designs.
Urinalysis (glucosuria) (three studies): The sensitivity ranged from 7% (specificity 98%) to 36% (specificity 98%). The specificity ranged from 84% (sensitivity 27%) to 98% (sensitivity 7% and 36%). The PPV ranged from 7 to 27%. RPG: At a threshold of 7.0mmol/L within 2 hours of eating and 6.4mmol/L otherwise (2 studies), sensitivities of 17% (specificity 99%) and 16% (specificity 96%) were reported. The PPVs were 4.5% and 47%. With a lower threshold of 6.1mmol/L within 2 hours of eating (1 study), the sensitivity was 46% and the PPV 12%. A study using a threshold of 6.0mmol/L within 2 hours of eating found sensitivities of 41 to 58% and specificities of 74 to 96%, depending on the time of day at which the test was performed.
FPG: With a threshold of 5.3mmol/L (1 study), the sensitivity was 48% and the specificity 97.5%. At a threshold of 4.8mmol/L (1 study), the sensitivity was 81% and specificity 76%. At a threshold of 4.9mmol/L (2 studies), sensitivities of 80% (specificity 40%) and 88% (specificity 78%) were reported, with a PPV of 1.3% in one of the studies. With a threshold of 4.3mmol/L (1 study), the sensitivity was 93% and the specificity 38.5%.
GCT: In a study using a threshold of 10.3mmol/L, sensitivity was reported to be 38%, specificity 96% and PPV 79%. At a threshold of 8.3mmol/L (3 studies), the sensitivities were 96% and 74% (specificity 90% for this study) and the PPVs ranged from 24 to 29%. In a study using a threshold of 8.0 mmol/L, the sensitivity was 82%, specificity 88% and PPV 27%, while a study with a threshold of 7.9 mmol/L found a sensitivity of 79%, a specificity of 87% and a PPV of 15%. At a threshold of 7.8 mmol/L (3 studies), the measured sensitivities were 86% (PPV 28%) and 96% (specificity 84% and PPV 25%), while the third study assumed a sensitivity of 100% and found a specificity of 83% and PPV of 15%. One study used ROC analysis to determine the optimal threshold of 7.5mmol/L, which gave a sensitivity of 100%, a specificity of 80% and a PPV of 21%. One study, assessing the reliability of the GCT at the 7.5mmol/L threshold, found that 27% of women would have been missed if only one test was carried out instead of tests on two consecutive days.
Screening with combined GCT and risk factors: Five studies assessed a combination of GCT and risk factors, using a variety of thresholds. At a threshold of 7.2mmol/L and using greater than or equal to 24 or 25 years' maternal age as a risk factor (3 studies), the sensitivity ranged from 85 to 92%; the PPV in one of these studies was 14%. At a threshold of 7.8mmol/L for women with at least one risk factor (2 studies), the sensitivities were 95% and 86% (with specificity 65% and PPV 23% in one study). In a study using a threshold of 7.9mmol/L, the sensitivity ranged from 53% (specificity 93%) to 88% (specificity 82%) and the specificity ranged from 80% (sensitivity 62%) to 93% (sensitivity 53%), depending on the combination of risk factors used. At a threshold of 8.3mmol/L (3 studies), the sensitivity ranged from 62% (using at least 30 years' maternal age alone as the risk factor) to 95% (using an age threshold of at least 24 years); one of the studies reported a specificity 79% (sensitivity 83%), and two reported PPVs of 31% and 32%.
Several studies assessed the performance of alternative sources of glucose; results for the individual studies are reported in the paper. Results from several studies that assessed the value of fructosamine levels were given. Other tests for which results were reported include: fructosamine (four studies), foetal abdominal transverse diameter (one study), and glycosylated haemoglobin. The paper also reports results for the comparison of GCT with other tests in one or two studies, the impact of different diagnostic criteria on test performance, and the psychological impact of screening.
Cost information
The reviewers reported that several studies (nine from the USA and one from Australia) had assessed the costeffectiveness of GDM screening in terms of the cost per case of GDM detected. These estimates were based on screening with GCT followed by diagnosis with GTT, and varied according to the time of publication, the GCT threshold, the population, and whether GCT was combined with risk factor screening. The estimates varied from US$173 to US$2,733. No UK data were available.
